Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Is Chemours (CC) a Great Stock for Value Investors?
by Zacks Equity Research
Is Chemours (CC) a great pick from the value investor's perspective right now? Read on to know more.
5 Must-Buy Mid Cap Winners of Past Month With More Upside
by Nalak Das
We have narrowed our search to five mid-cap stocks that have popped double-digit in the past month, with more upside. These are: LPX, GFF, PAG, CC and AVT.
Should You Buy Chemours (CC) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Are Basic Materials Stocks Lagging Carpenter Technology (CRS) This Year?
by Zacks Equity Research
Here is how Carpenter Technology (CRS) and Chemours (CC) have performed compared to their sector so far this year.
Chemours (CC) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Chemours (CC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Chemours (CC) Earnings and Revenues Top Estimates in Q1
by Zacks Equity Research
Chemours (CC) gains on strong volumes and higher prices amid headwinds from raw material cost inflation and logistics challenges in Q1.
Chemours (CC) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 58.70% and 14.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scotts Miracle-Gro (SMG) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
ScottsMiracle-Gro's (SMG) Q2 performance is likely to have benefited from strength in the U.S. Consumer segment and cost savings.
Andersons (ANDE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Andersons's (ANDE) Q1 performance is likely to reflect benefits from strong demand and high commodity and fertilizer prices.
TimkenSteel (TMST) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
TimkenSteel (TMST) is expected to have benefited, in the first quarter, from higher demand in industrial and energy end markets.
DuPont (DD) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DuPont (DD) is likely to have benefited from strong demand and productivity actions. However, higher raw material and logistics costs are expected to have hurt its Q1 results.
Why Chemours (CC) Might Surprise This Earnings Season
by Zacks Equity Research
Chemours (CC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Higher Prices Benefit Nutrien (NTR) in Q1 Earnings?
by Zacks Equity Research
Higher prices aided by strong demand and tight supply are likely to have driven Nutrien's (NTR) sales and margins in the first quarter.
FMC Corp (FMC) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
FMC Corp's (FMC) first-quarter performance is likely to reflect increased demand and pricing amid headwinds from higher input costs resulting from supply chain disruptions.
Westlake (WLK) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Westlake's (WLK) Q1 performance is likely to have benefited from higher demand trends for polyethylene and PVC resin.
Will Higher Selling Prices Drive Mosaic's (MOS) Q1 Earnings?
by Zacks Equity Research
Profitability across Mosaic's (MOS) Phosphates and Potash segments is expected to have boosted by higher average selling prices in Q1.
Intrepid Potash (IPI) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Intrepid Potash (IPI) is likely to have benefited from strong demand and higher net realized sales price per ton for its potash and Trio products in Q1.
Nutrien (NTR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Nutrien's (NTR) Q1 results are likely to have benefited from solid demand and higher prices for fertilizers, aided by the underlying strength in global agriculture markets.
Chemours (CC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Chemours (CC) closed at $32.64, marking a +1.15% move from the previous day.
LyondellBasell (LYB) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
LyondellBasell's (LYB) Q1 performance is likely to have benefited from strong consumer-driven demand and favorable market trends.
Chemours (CC) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Chemours' (CC) first-quarter performance is likely to reflect the increasing adoption of Opteon refrigerants and the benefits of cost-cutting measures.
Mosaic (MOS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Mosaic (MOS) is likely to have benefited from strong demand and prices for phosphate and potash in the first quarter.
Huntsman (HUN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Huntsman's (HUN) Q1 performance is likely to have benefited from health demand and prices for MDI amid headwinds from higher input and logistics costs.
Celanese (CE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Celanese's (CE) Q1 performance is likely to have benefited from productivity actions, investments in high-return organic projects and strategic acquisitions.
Linde (LIN) Gears Up to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Higher industrial production is likely to have aided Linde (LIN) in Q1.